Introduction
Rheumatoid arthritis is an autoimmune disease in which inflammation of the cells lining the synovium produces pain, swelling, and progressive erosion of the synovial joints. Methotrexate (MTX), an antiproliferative and immunosuppressive agent, is the drug of choice in the treatment of the disease. 1 MTX is a folic acid antagonist used alone or in association with other therapeutic agents; however, MTX has an extensive toxicity range, which is the main cause of therapy withdrawal. MTX treatment is discontinued in 8%-19% of patients due to adverse reactions that include gastrointestinal, hepatic, renal, pulmonary, and hematological disturbances, and may also affect the central nervous system. 2 Overall, 26% of patients discontinued MTX treatment due to poor response, high toxicity, or both. Thus, in addition to the relatively high toxicity, variability, and unpredictability of the pharmacological action, there are also drawbacks to the use of MTX treatment for rheumatoid arthritis. 3 The interindividual variation in both effective MTX dose level and in toxicity has been ascribed to genetic polymorphisms. 3 These polymorphisms affect receptors related with the transport of MTX into the cell, such as the reduced folate receptor and membrane-associated folate receptors, as well as enzymes involved in folate metabolism such as 5,10-methylenetetrahydrofolate reductase and thymidylate synthase. 4 Genetic polymorphisms affecting the folate metabolic pathway and MTX transporters modify the toxicity of the drug, but do not seem to influence the efficacy of the drug. 5 To circumvent the systemic toxicity of MTX, the use of the intra-articular route of drug administration was tested, but the results were not satisfactory because MTX is rapidly cleared from the joint cavity. 6 In previous studies, we showed that nanoemulsions (LDE) that resemble the lipid structure of low-density lipoprotein (LDL) have the ability to concentrate in tissues undergoing proliferating processes, such as in malignant neoplasias or atherosclerotic lesions. 7, 8 LDE binds to LDL receptors, which are upregulated in those tissues, and this is the mechanism that favors the uptake and intracellular concentration of LDE via the receptor-mediated endocytosis pathway. When antiproliferative agents, such as paclitaxel, carmustine, or etoposide were associated with LDE, they promoted inhibition of tumor growth in murine oncologic models and they also inhibited the development of atheromatous lesions in rabbits with induced atherosclerosis. [9] [10] [11] [12] [13] Association with LDE resulted in a remarkable reduction of the toxicity of those drugs.
In a recent study, we described a novel formulation consisting of an MTX derivative, di-dodecyl-MTX, associated with LDE. LDE-MTX is stable and, compared to commercial MTX, showed superior cytotoxicity as tested in cultured leukemia cells. 14 The aim of the current study is to evaluate the effect of intra-articularly injected LDE-MTX on the inflammatory process in a rabbit model of arthritis in comparison with treatment using commercial MTX also administered by this route.
Methods

LDE preparation and association of MTX
LDE-MTX was prepared from a lipid mixture composed of 100 mg of cholesteryl oleate, 200 mg of egg phosphatidylcholine (Lipoid GMBH, Ludwigshafen, Germany), 10 mg of triglycerides, 12 mg of cholesterol, and 60 mg of MTX. [14] [15] [16] The aqueous phase consisting of 100 mg of polysorbate 80 Tween 80 (Merk, Hohenbrum, Germany) and 10 mL of TrisHCl buffer pH 8.05 was kept at room temperature. The preemulsion was obtained by adding the hydrophilic phase to the oil phase by ultrasonic radiation until complete dissolution of the drug. Emulsification of all lipids, MTX, and the aqueous phase was obtained by high-pressure homogenization using an Emulsiflex C5 homogenizer (Avestin Inc, Ottawa, Canada). After 30-40 minutes of homogenization at a constant temperature, the nanoemulsion was centrifuged at 1800 × g for 15 minutes to separate the emulsified and unbound MTX that precipitates upon centrifugation. The nanoemulsion was sterilized by passage through a 0.22 µm pore polycarbonate filter (EMD Millipore Corporation, Billerica, MA, USA) and kept at 4°C until it was used. The incorporation of MTX to LDE was measured before its injection into animals by highperformance liquid chromatography. Prepared as described, the average diameter of the LDE-MTX particle was 60 nm, as measured by Laser Light Scattering method performed using the ZetaPALS Zeta Potential Analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA).
LDE uptake by the joint LDE at a 100 µL volume labeled with [ 14 C]-cholesteryl ether (PerkinElmer Inc, Boston, MA, USA) was injected intravenously into the ear vein of three rabbits. Animals were kept in individual cages for 24 hours, when they were sacrificed. Fragments of synovial tissue were excised and kept in cold saline solution prior to lipid extraction with chloroform/ methanol (2:1 v/v). 17 After lipid extraction, the solvent was evaporated under N 2 flow and resuspended with 500 µL of chloroform/methanol (2:1 v/v), and half of the suspension was placed separately into vials with 5 mL scintillation solution (PerkinElmer, Inc., Boston, MA, USA), and the radioactivity was measured with a Packard 1600 TR liquid scintillation spectrometer (Packard BioScience, Inc, Palo Alto, CA, USA).
Arthritis induction
The Animal Ethics Committee of COBEA (Brazilian College of Experimental Animals) approved all experimental procedures performed on animals in accordance with The Universities Federation for Animals Welfare. Antigen-induced arthritis (AIA) was induced in New Zealand White rabbits. Animals were sensitized with 5 mg of methylated bovine serum albumin (mBSA, Sigma-Aldrich Co, St Louis, MO, USA) in 1 mL of Freund's complete adjuvant submit your manuscript | www.dovepress.com
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(Gibco ® ; Life Technologies Corporation, Carlsbad, CA, USA) and 1 mL of sterile saline in multiple injections at subcutaneous and muscular sites in the supra-escapular and gluteal region, respectively. Fourteen days after immunization, the animals were boosted with five intradermical injections of 1 mg/mL of mBSA, and the onset of Arthus reaction with central necrosis was observed 24 hours later.
The animals used were those which appropriately responded to the cutaneous challenge. Arthritis was induced in the knee joint by injection of 0.5 mL of a sterile solution of mBSA (2 mg/mL) into the intra-articular cavity. The contralateral joint was injected with saline. Forty-eight hours after the intra-articular challenge, the animal was sacrificed by an overdose of a mixture of xylazine 15 mg/kg (Bayer AG, São Paolo, Brazil) with ketamine 150 mg/kg (Parke Davis; Pfizer Inc, São Paolo, Brazil).
Intra-articular injections of LDE-MTX, LDE, and commercial MTX
Twenty-four hours after arthritis induction, animals were allocated into seven groups: one group was intra-articularly injected with a single dose of saline solution (300 µL, n = 9); the other four groups were intra-articularly injected with LDE-MTX at decreasing doses of 0.0625 (n = 4), 0.125 (n = 4), 0.25 (n = 4), and 0.5 µmol/kg (n = 8); the last group was intra-articularly injected with a single dose of commercial MTX (0.5 µmol/kg, n = 4) and LDE alone (300 µL, n = 4).
Synovial fluid sampling
Immediately after sacrifice, 2 mL of saline containing ethylenediaminetetraacetic acid (1 mg/mL) were injected into each knee joint. Synovial fluid was collected with a needle, and the joint was then opened to recover the remaining fluid. The collected synovial fluid was diluted, and the total cell count was performed by light microscopy. The differential cell count was performed in smears prepared from cell pellet and stained by Giemsa.
Assessment of vascular permeability
Before the induction of arthritis, the animals were injected intravenously with 20 mg/kg of Evans Blue (INLAB, São Paulo, Brazil) in a 2.5% saline solution. The dye binds to plasma proteins originating within a tagged macromolecule that crosses the endothelial barrier only when tissues are inflamed. The joint fluid was centrifuged and the optical density was assessed by a colorimetric method at 630 nm. The dye concentration in the joint was estimated from a standard curve of a weighed sample of Evans Blue serial dilutions in saline solution. Results are expressed as µg of protein/mL of synovial fluid.
Synovial membrane infiltrate
Synovial membrane sections (5 µm) were stained with hematoxylin and eosin for the quantification of cell infiltrate under light microscopy. The histological analysis was performed using at a 400× magnification in the microscope (BX-51; Olympus America Inc, Center Valley, PA, USA) fitted with a camera (Q Color 5; Olympus America Inc). Micrographs were processed using Image ProPlus software (version 6.0; Media Cybernetics Inc, Bethesda, MD, USA). Infiltrating leukocytes were assessed in five distinct digitalized panels per tissue fragment with a minimum of approximately 100 µm 
Cytokines in synovial fluid
Six cytokines (IL-1β, IL-6, IL-10, IL-17, and tumor necrosis factor-α) were measured simultaneously in the synovial wash samples using a microsphere-based multiplex immunoassay kit (EMD Millipore Corporation, Billerica, MA, USA) according to the manufacturer's instructions, using the saline, LDE, commercial MTX, and LDE-MTX (0.5 µmol/kg) experimental groups consisting of four rabbits.
Statistics
Results are expressed as means ± standard error. The data have been subjected to repeated analysis of variance. Post hoc analysis was conducted using the Kruskal-Wallis multiple comparison tests. In all analyses, P , 0.05 was considered statistically significant.
Results
LDE uptake by the joint
As analyzed in three AIA rabbits injected with radioactive LDE, the amount of the nanoemulsion 3 H-cholesterol oleate ether label found in the synovial membrane of the arthritic joints was roughly 2.5 times that found in the control, salineinjected joint.
Leukocytes count in synovial fluid
As shown in Figure 1 , treatment of the AIA animals with intra-articular injection of commercial MTX at a 0.5 µmol/kg dose had no effect on the total leukocyte count in the synovial fluid as compared with the controls (16, promote any alteration in the cellular influx of the joint (17,375 ± 1645 cells/mm 3 ). In contrast, when the animals were treated with the intra-articular injection of LDE-MTX at the equivalent MTX dose (0.5 µmol/kg), there was a significant reduction in the total number of leukocytes in the synovial fluid (8416 ± 997 versus 13,346 ± 1144 cells/mm 3 , P = 0.004). In Figure 1 , it is also shown that LDE-MTX had an apparent dose response curve, so that the lower LDE-MTX doses elicited lower reductions in the leukocyte count in the synovial fluid. However, only leukocyte count reductions produced by 0.5 and 0.25 MTX µmol/kg dose levels were found to be statistically significant when compared to the controls. Regarding the differential count (Figure 1 ), a preferential population of cells affected by LDE-MTX injection was not found, so it seemed as though both mononuclear and polymorphonuclear cell counts were equally reduced by this treatment.
Synovial membrane infiltrate
Microscopic analysis of the synovial membrane of rabbits with 48 hours AIA that were intra-articularly treated with LDE-MTX is summarized in Figure 2 . Figure 2A shows a low number of infiltrated leukocytes (0.41 ± 0.01 cells/100 µm 2 ) observed in the synovial membrane of a joint without arthritis. In Figure 2B , there is high leukocyte infiltration observed in the 48th hour of AIA in the untreated animals (23.46 ± 2.6 cells/100 µm 2 ). The efficacy of intra-articular treatment with LDE-MTX (0.5 µmol/kg) is shown in Figure 2C (2.96 ± 0.44 cells/100 µm 2 , P , 0.0001). The leukocyte infiltrate in this tissue was very similar to those extracted from the joint without arthritis. In Figure 2D and E, it is clear that the intra-articular injection of submit your manuscript | www.dovepress.com Dovepress Dovepress commercial MTX or LDE did not alter the leukocyte infiltrate in the arthritic synovial membrane (19.1 ± 1.2 and 18.2 ± 2.7 cells/100 µm 2 , respectively). The cell counting data analysis exhibited in Figure 2 fully confirms that intra-articular treatment using LDE-MTX was effective in reducing infiltrated cells, although commercial MTX and LDE alone had no effect.
Synovial vascular permeability
As shown in Figure 3 , the intra-articular treatment with LDE-MTX at a 0.5 µmol/kg dose had the ability to reduce the protein leakage to the synovial fluid collected from the arthritic joints (3.36 ± 0.66 versus 5.31 ± 0.59 µg of protein/mL, P = 0.032). In contrast, treatment with an equivalent dose of commercial MTX or LDE alone had no significant effect on protein leakage (4.54 ± 0.36 and 5.5 ± 1.41 µg of protein/mL, respectively versus AIA the difference was not significant [P = 0.221, ANOVA test]).
Cytokines in synovial fluids
Compared to the rabbits with AIA (n = 4), animals treated with intra-articular LDE-MTX at a 0.5 µmol/kg dose (n = 4) showed diminished levels of IL-17 in synovial fluid (AIA 263.2 ± 65.6; LDE-MTX 17.6 ± 9.9 pg/mL), although the values did not reach significant levels (P = 0.05). Interferon gamma levels were also reduced by LDE-MTX treatment, although the values did not reach signif icant levels (P = 0.05). Commercial MTX or LDE treatments did not alter the cytokine level in the arthritic joint. Regarding the determination of IL-1β, IL-6, IL-10, and tumor necrosis factor-α, levels of these cytokines were undetectable in the fluid samples. This was probably due to the excess dilution of the synovial fluid samples that were collected by washing the joint with saline solution.
Discussion
The LDE-MTX preparation, as administered by an intra-articular route, was clearly effective in reducing the afflux of inflammatory cells to the joint. In contrast, the commercial MTX preparation at the same dose and route of administration had no effect, confirming the findings from previous literature. 20 The intra-articular route frequently used to treat inflammatory processes of the joint has failed in regards to commercial MTX. This occurs because MTX is rapidly exited from the joint cavity, resulting in low drug concentration. 21 An alternative intra-articular approach was tested in rats, in which MTX was complexed with hyaluronic acid; this was also not successful in treating the inflammation due to fast clearance from the joint cavity. 22 Liposome technology was also attempted to preserve MTX efficacy when injected intra-articularly. The uptake by rabbit synovial tissues of MTX enveloped in liposome systems was low, but yet greater than MTX alone. Liposomal MTX also had a more intense therapeutic effect than MTX alone. 20, 21 Other studies performed in rats reported that liposomes with different composition and structure had different therapeutic effects due to the variations in intra-synovial retention time. 23 Intra-articular liposomal MTX reduced pro-inflammatory interleukins, but only when injected on the same day of the arthritis induction. Apparently, none of the liposomal formulations had an effect on the established arthritis (ie, arthritis that was induced in the animals for more than 24 h). Other MTX lipid-based carriers were also described in the literature for other therapeutic purposes; some examples include chylomicron-like emulsions being used as MTX carriers for cancer treatment, and emulsionassociated MTX for topical use in psoriasis treatment. 24, 25 LDL is removed from circulation by specific LDL or by lipoprotein-receptor related proteins, used as ligand apo B, which is the unique apo found in LDL. LDE, a stable nanoemulsion that resembles the lipid structure of native LDL, is made without apo B; however, in contact with plasma or other corporeal fluids, LDE acquires apo E from the other lipoproteins. 26 Apo E is also an LDL-receptor ligand that has a much greater affinity for the receptor than apo B. Apo E is a ubiquitous protein found in body fluids and is present in substantial amounts in the joint fluid as secreted by synovial cells, and also by monocytes in inflamed joints. 27 Therefore, when injected into the joint, LDE containing drug can pick-up apo E in the synovial fluid and is thus internalized into synovia cells by the LDL receptor endocytic pathway. In a previous study, we had shown that the intralesional injection of the nanoemulsion into breast carcinoma tissue resulted in a great concentration of LDE in the tumor. 28 Likewise, the tropism of LDE for the inflamed synovial tissues was shown in the present experiment, whereby the injected radioactively labeled LDE was 2.5 times more concentrated in the arthritic joint than in the normal joint.
As we recently reported, LDL receptors offer a much more efficient internalization mechanism for MTX cell uptake than the folate receptors that internalize the commercial MTX formulation. 14 We observed that the uptake of LDE-MTX by cultured neoplastic K562 and HL60 cells was considerably greater than that of commercial MTX. The greater uptake of LDE-MTX led to a much greater level of cytotoxicity than commercial MTX. Therefore, LDE use as a carrier offers an efficient mechanism through which to optimize MTX pharmacological action which, in the commercial preparation, is limited by poor cell uptake. 14 The experimental model used in this study is advantageous insofar as it resembled human inflammatory arthritis in many respects, including the resulting synovitis. 29 This increased uptake of LDE-MTX may account for the strong anti-inflammatory effect of this new complex, supported by the finding of a remarkable decrease in synovial cell infiltrates. Reinforcing this finding, a dose response curve was observed in the other two inflammatory parameters that were evaluated.
With respect to the effect of the different treatments on the cytokines present in the synovial fluid, it is remarkable that LDE-MTX, and not MTX alone, had the ability to diminish the cytokine levels, a finding that fully corroborates the antiinflammatory actions on cell counts in both synovial fluid and across the synovial membrane.
The single dose of 0.5 µmol/kg of body weight injected into the animal joint was devoid of toxicity. Accordingly, in experiments in which LDE-MTX was intravenously injected into rabbits at a high, 4 mg/kg body weight/week dose, no hematological, renal, or hepatic toxicities, weight loss, or food intake diminution were observed during the one month treatment period. 30 Drug delivery systems may improve the physicochemical properties as well as increase the bioavailability of the therapeutic drug used for treatment, while decreasing the toxicity level of existing agents. In a sense, the use of these systems makes room for the reformulation of existing drugs, which is often more cost-effective and faster than the development of new drugs. 31 The results of the current study clearly confirm these assumptions by showing that a drug that is virtually inactive when injected into the joint 48 hours after arthritis induction was endowed with strong anti-inflammatory action in association with LDE. In conclusion, the intraarticular injection of LDE-MTX seems to be a promising drug delivery strategy for treating arthritis.
